ZYDUSLIFE
Zydus Lifesciences
Each stock's 10,000-path forecast, rendered as light.
Zydus Lifesciences (ZYDUSLIFE) Stock Analysis & Case Study
Is ZYDUSLIFE a good buy? The data-driven verdict.
Zydus Lifesciences (ZYDUSLIFE) trades at ₹1,086,on the numbers it worth a closer look, a Downstox Snapshot Score of 65/100.
On the numbers, Zydus Lifesciences (ZYDUSLIFE) worth a closer look, a Downstox Snapshot Score of 65/100, weighing fairly valued at 20.1× earnings, ROE of 21.2%, a 44% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
ZYDUSLIFE fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is ZYDUSLIFE overvalued? ZYDUSLIFE P/E vs its Pharma
ZYDUSLIFE's P/E of 20.1× sits below the Pharma peer median of 25.7×, so on earnings it screens cheaper than peers, while its 0.09% dividend yield is below the peer median of 0.51%.
ZYDUSLIFE share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of ZYDUSLIFE history (-0%/yr drift, 24%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ZYDUSLIFE 2027 | ₹761 | ₹1,035 | ₹1,402 | -3% |
| ZYDUSLIFE 2028 | ₹644 | ₹1,006 | ₹1,550 | -6% |
| ZYDUSLIFE 2029 | ₹566 | ₹969 | ₹1,659 | -9% |
| ZYDUSLIFE 2030 | ₹498 | ₹936 | ₹1,749 | -13% |
| ZYDUSLIFE 2031 | ₹455 | ₹902 | ₹1,800 | -16% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ZYDUSLIFE goes up, or doubles?
The bull case for ZYDUSLIFE
- A 20.1× P/E sits in the fair-value band, neither cheap nor stretched.
- High return on equity (21.2%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
- Strong ROCE (21.2%) shows the core business earns well above its cost of capital.
- Relatively low volatility (24%/yr), a steadier ride than the typical mid/small-cap.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,659.
The bear case & risks
- The probability model is cautious 12 months out, only a 44% chance of finishing above today's price.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹566.
ZYDUSLIFE volatility & expected range, how bumpy is the ride?
Over the last 2.0 years ZYDUSLIFE compounded at -0%/year with annualized volatility of 24%. That volatility implies a 1-year 80% range of ₹761–₹1,402, the honest backbone behind any single price target.
ZYDUSLIFE price forecast, the full 60-month probability fan
ZYDUSLIFE price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ZYDUSLIFE hits common targets within the simulated horizon?
Full multi-horizon detail on the ZYDUSLIFE price target & forecast page.
ZYDUSLIFE Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. ZYDUSLIFE scores 4/9,mixed financial health.
ZYDUSLIFE MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy ZYDUSLIFE with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 26.9% | 3.7× |
| Zerodha | 23.0% | 4.3× |
| DhanCHEAPEST | 22.0% | 4.5× |
Compare every broker on the ZYDUSLIFE MTF page.
ZYDUSLIFE vs peers,Pharma comparison
About Zydus Lifesciences: sector, index & market-cap context
Zydus Lifesciences (ZYDUSLIFE) is a large-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 50 index group, with a market capitalisation of ₹1.09L Cr. See more Nifty 50 stocks.
How the ZYDUSLIFE Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Zydus Lifesciences's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ZYDUSLIFE analysis, FAQs
Is Zydus Lifesciences (ZYDUSLIFE) a good buy?
On the numbers, Zydus Lifesciences (ZYDUSLIFE) worth a closer look, a Downstox Snapshot Score of 65/100, weighing fairly valued at 20.1× earnings, ROE of 21.2%, a 44% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ZYDUSLIFE overvalued or undervalued?
ZYDUSLIFE trades at 20.1× earnings versus a peer median of 25.7×, so it screens cheaper than its Pharma peers.
What is the ZYDUSLIFE share price target for 2031?
ZYDUSLIFE's probability-weighted 2031 median target is ₹902, with an 80% range of ₹455–₹1,800 (10,000-path Monte-Carlo).
What is the probability ZYDUSLIFE doubles in 5 years?
The modelled probability of ZYDUSLIFE reaching ₹2,142 (2×) within 5 years is 5%.
What is the bull case for ZYDUSLIFE?
A 20.1× P/E sits in the fair-value band, neither cheap nor stretched. High return on equity (21.2%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise. Strong ROCE (21.2%) shows the core business earns well above its cost of capital.
What are the risks in ZYDUSLIFE?
The probability model is cautious 12 months out, only a 44% chance of finishing above today's price.